CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
lovastatin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00462280
NCT00462280Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

National Cancer Institute (NCI)·interventional·Posted Apr 19, 2007·Updated Oct 31, 2014

In Brief

A Phase 2 clinical trial evaluating lovastatin, placebo, and 2 other interventions for Precancerous Condition and 3 related conditions. Completed, enrolled 80 participants across 3 sites.

Detailed Summary

The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or placebo works in treating patients at high risk of melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrecancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 19, 2007
Enrollment StartMay 1, 2007
Primary CompletionApr 1, 2011
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 19.2 years ago

Interventions

lovastatindrug

Given PO

placeboother

Given PO

biopsyprocedure

Correlative studies

laboratory biomarker analysisprocedure

Correlative studies